Navigation Links
Kendle Invites You to Attend its First Quarter 2008 Earnings Conference Call and Webcast
Date:4/24/2008

and Canada should dial (800) 399-0069. Participants outside North America should dial (706) 643-3694. A replay will be available through 5 p.m. Eastern Time on June 6 by dialing (706) 645-9291 and entering conference ID number 41241978.

About Kendle

Kendle (Nasdaq: KNDL) is a leading global clinical research organization providing the full range of early- to late-stage clinical development services for the world's biopharmaceutical industry. Our focus is on innovative solutions that reduce cycle times for our customers and accelerate the delivery of life-enhancing drugs to market for the benefit of patients worldwide. As one of the fastest-growing global providers of Phase I-IV services we offer experience spanning 90 countries, along with industry-leading patient access and retention capabilities and broad therapeutic expertise, to meet our customers' clinical development challenges. Kendle was named "Top CRO to Work With" in the Thomson CenterWatch 2007 survey of U.S. investigative sites and "Best CRO" for 2007 and 2006 by leading global pharmaceutical publication Scrip World Pharmaceutical News.

Additional information and investor kits are available upon request from Kendle, 441 Vine Street, Suite 1200, Cincinnati, OH 45202, United States or from the company's Web site at http://www.kendle.com

(Logo: http://www.newscom.com/cgi-bin/prnh/20030429/KNDLLOGO )


'/>"/>
SOURCE Kendle
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Kendle to Present at the Lehman Brothers Eleventh Annual Global Healthcare Conference
2. Kendle Leaders Adopt 10b5-1 Trading Plans
3. Kendle to Present at the 29th Annual Raymond James Institutional Investors Conference
4. Kendle Hires Satish Tripathi, PhD, RAC as Vice President, Global Regulatory and Quality
5. Kendle to Present at the Wachovia 2008 Healthcare Conference
6. Kendle Appoints Former MHRA Head of Biologics as Principal Regulatory Affairs Consultant
7. Kendle Named Best CRO for Second Consecutive Year by Leading Global Pharmaceutical Publication Scrip
8. Kendle Invites You to Attend Its Third Quarter 2007 Earnings Conference Call and Webcast
9. Kendle to Present at the Natixis Bleichroeder Hidden Gems Conference
10. Kendle to Present at the UBS Global Life Sciences Conference
11. Kendle to Present at Bear Stearns 20th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2009)...PRNewswire-USNewswire/ -- Nearly 600 medical resea...ders today convened to explore novel development a... inaugural Partnering for Cures meeting. ,, ...Milken Institute, convened Partnering for Cures ...o turn a scientific discovery into an accessible t...
(Date:12/2/2009).... 2 /PRNewswire-FirstCall/ - Oncolytics Biotech In...Q: ONCY ) announced today that in connection with ...riters have exercised in full their over-allotment... Each unit is comprised of one common share and 0.... at a price of US$3.00 per unit. Each whole common...
(Date:12/2/2009)...ss., Dec. 2 TechConnect World, an ...development and product integration in cleantech, ... 11th deadline for technology abstracts and busine...Connect World, in association with the Nano Scienc...echnology and Sustainable Industries Organization ...
(Date:12/2/2009)... Dec. 2 /PRNewswire-Asia-FirstCall/ -- Emerald Dai...ulletin Board: EMDY), a leading,producer and distr...er and,soybean products in China, today announced ...sue of US Food & Drink Executive, a quarterly ...ves in the food and beverage industry. , ...
Breaking Biology Technology:Medical Research Leaders Explore Novel Strategies to Expedite the Search for Cures 2Oncolytics Biotech(R) Inc. Announces Exercise of Underwriters' Over-Allotment Option 2Oncolytics Biotech(R) Inc. Announces Exercise of Underwriters' Over-Allotment Option 3Oncolytics Biotech(R) Inc. Announces Exercise of Underwriters' Over-Allotment Option 4Deadline Approaching for Largest Commercialization Event for Nanotech & Clean Technologies 2Deadline Approaching for Largest Commercialization Event for Nanotech & Clean Technologies 3Emerald Dairy To Be Featured in Spring Issue of US Food and Drink Executive 2
...ng top 10 most promising drugs ...Newswire-FirstCall/ - Resverlogix Corp,s,("Resverl...I drug,candidate, RVX-208 has been selected as one...se (CVD) drugs available for strategic partnering ... Information, a leading,provider of business infor...
...CAGO, July 9 Brinks Hofer Gilson & Lione, one of ... U.S., announces the opening,of a new office in th... two,local patent attorneys, Allen R. Baum and Jos...ffice. Mr. Baum and Mr. Elliott, formerly with The...he office will officially,be open for business on ...
... DIEGO, July 9 Pacira Pharmaceuticals, Inc., an,a...announced the,appointment of a new Board member an...mpany,s management team. Gary Pace, Ph.D, joins th...al executive with more than,30 years of experience...xperience to Pacira as the founder and past Chairm...
Other Biology Technology:Industry Leaders Select Resverlogix's RVX-208 2Industry Leaders Select Resverlogix's RVX-208 3Brinks Hofer Gilson & Lione Expands to High-Tech Raleigh/Durham Area; Adds Accomplished Patent Attorneys to Its New Office 2Brinks Hofer Gilson & Lione Expands to High-Tech Raleigh/Durham Area; Adds Accomplished Patent Attorneys to Its New Office 3Pacira Pharmaceuticals, Inc. Adds Board Member and Key Senior Management 2
(Date:12/3/2009)... Van Andel Research Institute (VARI) researchers ...scisic acid (ABA) works at the molecular level to ... as drought and cold. Their findings, published i...that thrive in harsh environments around the world...ould also have implications for stress disorders i...
(Date:12/3/2009)...the design of the upcoming forest deal at Copenhag...ing to a scientist at the University of Leeds. ,... that at least 50% of the carbon credit payments t... Emissions from Deforestation and Degredation), sh...r property rights assured. , "There is the poten...
(Date:12/3/2009)... the U.S. Department of Energy,s (DOE) Brookhaven ...ndian Institute of Science has made a major step i...nformation in DNA that is necessary to carry out i...shed in the December 1, 2009 edition of Nature St...proteins responsible for interacting at specific s...
Breaking Biology News(10 mins):VAI researchers find long awaited key to creating drought resistant crops 2VAI researchers find long awaited key to creating drought resistant crops 3Forest deal at Copenhagen must avoid creating 'carbon refugees' 2Grooving down the helix 2Grooving down the helix 3First human gene implicated in regulating length of human sleep 9568 1First human gene implicated in regulating length of human sleep 9568 2First human gene implicated in regulating length of human sleep 9568 3Thomson Reuters Launches New Developments to Support Synthetic Chemists 54473 1Thomson Reuters Launches New Developments to Support Synthetic Chemists 54473 2Queen of Soul Foods Grandson on Mission to Get Harlem Kids to Eat Healthier 54472 1Queen of Soul Foods Grandson on Mission to Get Harlem Kids to Eat Healthier 54472 2Queen of Soul Foods Grandson on Mission to Get Harlem Kids to Eat Healthier 54472 3
...ological function for a soccer ball-shaped nanopar...lergic response, setting the stage for the develop...ase is the sixth leading cause of chronic disease ... have been developed to control allergy, no cure h... field of medicine known as nanoimmunology. , T...
...RGX) today announced the publication in the June 2...lts from the first ever gene therapy trial for Par...ne transfer into a patient’s own brain cells for a...bel Phase 1 study, conducted in 12 patients with a...ck of adverse events related to the gene therapy p...
... Cell Research Enhancement Act, which would expand... AAAS, the world’s largest general scientific soci...anning all parties and faiths that supports this b...stem cell research is an extremely promising appro...vastating conditions like diabetes, spinal cord in...
Other Biology News:Researchers develop buckyballs to fight allergy 2Gene therapy study shows safety and statistically significant improvement in Parkinson's disease 2Gene therapy study shows safety and statistically significant improvement in Parkinson's disease 3Gene therapy study shows safety and statistically significant improvement in Parkinson's disease 4AAAS decries latest stem cell veto 2AAAS decries latest stem cell veto 3
ELISA Kit for Hepatitis B Surface Antigen Using GoldMag-AS Microparticles from BioChain
HiTrap Streptavidin HP from GE Healthcare, formerly Amersham Biosciences
Rat Growth Hormone EIA Kit from Cayman Chemical
Prostaglandin D2-d4 from Cayman Chemical
Biology Products: